AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06299579
Drug: Placebo control group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
Trial: NCT04556370
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion simultaneous with subarachnoid block
Trial: NCT04556370
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different infusion dose of norepinephrine simultaneous with subarachnoid block
Trial: NCT04886193
Drug: FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year.
Trial: NCT05896046
Drug: SHR2554+ SHR1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
Trial: NCT05152277
Drug: HRS9531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC once
Trial: NCT05152277
Drug: HRS9531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC for multiple dose
Trial: NCT04965129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
Trial: NCT05019755
Drug: IN-A002(IN-115314) capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration of IN-A002(IN-115314), single dose
Trial: NCT04782804
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
Trial: NCT04861558
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of 250-850 mg/m2.
Trial: NCT05093998
Drug: AV5080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral hard gelatin capsules
Trial: NCT06517862
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.
Trial: NCT04849819
Drug: Corticosteroids, immunosuppressors, biological agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We do not prescribe new medications to patients but only observe their adverse effects on the eye.
Trial: NCT04731623
Drug: ION904
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ION904 will be administered by SC injection.
Trial: NCT04731623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sterile saline) will be administered by SC injection.
Trial: NCT05399030
Drug: ICP-332
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-332 will be administered as tablet
Trial: NCT05024747
Drug: NicoDerm CQ patch (GSK Dungarvan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.
Trial: NCT06281405
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w
Trial: NCT02683018
Drug: Smoked Cannabis High CBD/low THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
Trial: NCT02683018
Drug: Smoked Placebo Cannabis Low CBD/low THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
Trial: NCT04965506
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI362 administered subcutaneously (SC) once a week.
Trial: NCT04430283
Drug: FDY-5301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
Trial: NCT03734952
Drug: Neoadjuvant chemotherapy Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
Trial: NCT05124977
Drug: Antimicrobial Stewardship
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
Trial: NCT05124977
Drug: Standard management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
Trial: NCT06121492
Drug: Branched-chain amino acid
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
Trial: NCT05363670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04861948
Drug: IBI188
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT05053126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive an oral dose of placebo
Trial: NCT06305221
Drug: Opioid-free Analgesics (esketamine, dexmedetomidine)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
Trial: NCT06305221
Drug: Opioid Anesthetics (sufentanil and remifentanil)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
Trial: NCT01017822
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06362460
Drug: [14C] RAY1216
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg suspension containing 100μCi of \[14C\]RAY1216
Trial: NCT04591210
Drug: Angiotensin converting enzyme inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
Trial: NCT04625361
Drug: HEC122505MsOH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part2：Mulltiple doses once daily, up to 8 days
Trial: NCT06435182
Drug: OT202 conc 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily
Trial: NCT06435182
Drug: OT202 conc 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily
Trial: NCT06435182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
Trial: NCT05603754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
Trial: NCT06499727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Trial: NCT05399550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Intravenous Solution
Trial: NCT04334915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06194981
Drug: Oxaliplatin and capecitabine/ S-1 and capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
Trial: NCT05161637
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC590 490mg or 588mg
Trial: NCT05161637
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 20mL or 24mL
Trial: NCT05052541
Drug: THC/CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml
Trial: NCT05052541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution containing no active drug
Trial: NCT04526119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
Trial: NCT06082869
Drug: Protegera™ toothpaste (NaF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plaque Reduction
Trial: NCT06082869
Drug: Crest™ Cavity Protection toothpaste (NaF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plaque Reduction
Trial: NCT06121492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
Trial: NCT05624138
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
Trial: NCT05566288
Drug: Cytisinicline
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compressed film-coated tablet containing 3 mg cytisinicline
Trial: NCT05566288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
Trial: NCT04578015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive placebo
Trial: NCT05066633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be in the form of identical tablets and will be administered orally once daily.
Trial: NCT06000956
Drug: Jitongning tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.
Trial: NCT05129761
Drug: Syrup Hydryllin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
Trial: NCT00286364
Drug: Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05966493
Drug: lufepirsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
Trial: NCT05966493
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle without lufepirsen.
Trial: NCT05017714
Drug: Recombinant cytokine gene derived protein injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.
Trial: NCT06122987
Drug: Angiotensin II and hydrocortisone sodium succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
Trial: NCT05511025
Drug: AZD6234
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
Trial: NCT05511025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection
Trial: NCT06553846
Drug: Lutetium [177Lu]-FAP-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
Trial: NCT05424887
Drug: AK3280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Trial: NCT05424887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Trial: NCT06299813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
Trial: NCT05466734
Drug: PMR Tablet 135 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose (total daily dose of 270 mg)
Trial: NCT00264446
Drug: ADH300004
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06052293
Drug: ANG003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate four possible combinations of lipase, protease and amylase.
Trial: NCT05778461
Drug: L-ornithine L-Aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
Trial: NCT05778461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
Trial: NCT04996979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care
Trial: NCT06384833
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin C (solution) 500 mg IV q4h for 4 doses PO d0 Vitamin C (tablet) 100mg 5 tab PO BID for 45 days
Trial: NCT06007235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution in identical spray bottles
Trial: NCT06531278
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Patients are planned to receive fluorouracil (2400mg/m2; d1) of every cycle.~* 27 days a cycle
Trial: NCT05032781
Drug: Intra-arterial cold saline, minocycline, and magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See study design
Trial: NCT05697614
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group
Trial: NCT05697614
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxcarbazepine is used for focal type epilepsy, used in control group
Trial: NCT01101412
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given through CVC or PVC
Trial: NCT06081478
Drug: CD19/CD22-bispecific CAR-T cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.
Trial: NCT04795037
Drug: CU06-1004, Single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5
Trial: NCT04795037
Drug: CU06-1004, Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD
Trial: NCT04975711
Drug: HIP2105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT04975711
Drug: RLD2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug
Trial: NCT05680584
Drug: Melatonin 3 MG
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.1 mg/ kg melatonin in 10 ml apple juice 1 hour before induction of anesthesia
Trial: NCT06054035
Drug: Placebo matching Dapaglifolzin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Dapaglifolzin once daily for 2 years. Route of administration: oral.
Trial: NCT04807920
Drug: OnabotulinumtoxinA 100 UNT
RxNorm normalized name: onabotulinumtoxinA 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical injection
Trial: NCT05117346
Drug: CARDIX-101A, CARDIX-101B, CARDIX-101C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.
Trial: NCT05044117
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
Trial: NCT04975204
Drug: TQB3909 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3909 is an inhibitor targeting BCL-2 protein
Trial: NCT05305066
Drug: TNFi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
Trial: NCT05305066
Drug: JAKi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
Trial: NCT05806996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent volume of normal saline